Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Recently, a subset of natural killer T lymphocytes termed “cytokine-induced killer (CIK) cells” has been described. To build an international registry, we collected the clinical data and treatment of patients with cancer using CIK cells from the literature and the respective investigators. This registry is expected to set a new set of standards on the reporting of results from clinical trials using CIK cells. A standardized reporting system will accelerate discoveries and allows us to improve treatment to benefit the patients.
We searched in PubMed for “CIK cells clinical trials”.
Within the 867 matches found, 11 clinical trials with CIK cells were identified. Within these trials, 426 patients were treated, of which 313 were male, and 113 were female. Most trials included male patients with hepatocellular carcinoma, gastric cancer, and Hodgkin or non-Hodgkin disease. In 10 of 11 studies, autologous CIK cells were used. The total number of CIK cells injected ranged from 21.9 × 107 to 5.2 × 1010. The number of CIK cells used per infusion ranged from 7.2 × 106 to 2.1 × 1010. Patients were treated with up to 40 infusions of CIK cells. Of the 384 patients, where a clinical response was reported, 24 patients showed a complete response, 27 patients showed a partial response, 40 patients showed a minor response. The total response rate (RR) was 91/384 reported patients, 161 patients had a stable disease, 129 patients had progressive disease. A decrease in tumor volume was only described in three patients. Side effects of CIK cell treatment were minor. Interestingly, a reduction of hepatitis B virus load was described in patients undergoing treatment with CIK cells. Disease-free survival rates were significantly higher in patients treated with CIK cells than in a control group without CIK treatment.
Adjuvant immunotherapy with cytokine-induced killer cells may prevent recurrence and improve quality of life and progression-free survival rates in patients with cancer.
- Chan, JK, Hamilton, CA, Cheung, MK, Karimi, M, Baker, J, Gall, JG (2006) Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 12: pp. 1859-1867 CrossRef
- Kim HM, Lim J, Park S-K, Kang JS, Lee K, Lee CW et al (2007) Antitumour activity of cytokine-induced killer cells against human lung cancer. http://www.sciencedirect.com: International Immunopharmacology
- Lu, PH, Negrin, RS (1994) A novel population of expanded human CD 3+ CD 56+ cells derived from T cells with potent in vivo antitumour activity in SCID mice. J Immunol 153: pp. 1687-1696
- Margolin, KA, Negrin, RS, Wong, KK, Chatterjee, S, Wright, C, Forman, SJ (1997) Cellular Immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 157: pp. 231-240 CrossRef
- Schmidt-Wolf, IGH, Finke, S, Trojaneck, B, Denkena, A, Lefterova, P, Schwella, N, Heuft, H-G, Prange, G, Korte, M, Takeya, M, Dorbic, T, Neubauer, A, Wittig, B, Huhn, D (1999) Phase 1 clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81: pp. 1009-1016 CrossRef
- Shi, M, Zhang, B, Tang, Z-R, Lei, Z-Y, Wang, H-F, Feng, Y-Y, Fan, Z-P, Xu, D-P, Wang, FS (2004) Autologous cytokine-induced killer cell therapy in clinical trial phase 1 is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 10: pp. 1146-1151
- Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)
Journal of Cancer Research and Clinical Oncology
Volume 137, Issue 2 , pp 305-310
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- CIK cells
- Clinical trials
- International registry
- Industry Sectors
- Author Affiliations
- 1. Internal Medicine III, Center for Integrated Oncology (CIO), University of Bonn, Bonn, Germany
- 2. Clinical Study Support Core, CSSC, University of Bonn, Bonn, Germany
- 3. Institute of Pathology, University of Bonn, Sigmund-Freud-Str. 25, 53105, Bonn, Germany
- 4. John and Rebecca Moores Cancer Center, University of California San Diego, La Jolla, CA, 92037, USA
- 5. Med. Klinik und Poliklinik III, Center for Integrated Oncology (CIO), Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Str. 25, 53105, Bonn, Germany